Welcome to Integrative Practitioner

Integrative Practitioner is the leading online resource for integrative healthcare practitioners and professionals, providing its users with access to the most up-to-date information in integrative health news, events, and resources. We aim to support the wide spectrum of integrative healthcare practitioners with educational and informative content that is relevant to their patients and beneficial to their practice.

FEATURED ARTICLE:

Clinicians, Heal--and Celebrate--Yourselves! 
 
presented by James Gordon, MD
 
Like our patients, we must face life’s difficulties while celebrating the capacity for joy, peace, and inner wisdom we hold within ourselves. In this workshop, we’ll explore our own untapped gifts for self-healing as we discover the next steps in our own journey to greater personal health and professional contentment.

Read More >>

FEATURED WEBINAR:

Tori Hudson, NDFree Live Webinar: Botanicals in Select Immunity Issues Affecting the Thyroid, Joints, and Skin*

Presented by: Tori Hudson, ND
When/Time: June 9, 4-5:00pm ET


Botanicals can have a primary and secondary role in managing immunity disorders. Some of these botanicals have rich historic traditions with generations of empiric use; others do have some modern scientific research to prompt our use. In many cases, botanicals may need to be used in conjunction with conventional medicines to effectively manage these conditions. *

Botanicals to be discussed include: Ashwagandha, Tumeric longa and curcuminoids, Green tea, Borage oil, Berberine, Beupleurum, Aloe vera, Angrographis paniculata, Rose hips, Leonorus cardiaca, Melissa officinalis, Iris versicolor, and Bladderwrack.

Click HERE to register for this free webinar! 


On Demand Webinars

 
Please visit our On Demand Webinars page for other FREE  pre-recorded webinars!
Read More >>

SYMPOSIUM UPDATE:

Gain the Whole Perspective  

Make plans to attend the upcoming Integrative Healthcare Symposium focus on: the microbiome taking place October 9-10 in Hollywood, Florida. Learn from leading speakers and take a deeper look into the topic of microbiome and how it  impacts you and your patients. Visit the EVENT SITE today to learn more.

Researchers Discover New Biomarker for Predicting Liver Cancer Spread and Survival


New research has shown that a unique pattern of microRNAs, small RNA molecules that regulate gene activity, can accurately predict whether liver cancer will spread and whether liver cancer patients will have shorter or longer survival, even patients with early stage disease. The study, which appeared online January 7, 2008 in Hepatology, was conducted by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and colleagues at Ohio State University, Columbus, and the Liver Cancer Institute in Shanghai, China.

"The aggressive nature of hepatocellular carcinoma, a prevalent type of liver cancer, is largely due to its tendency to spread or recur after surgery," said the study's lead author, Anuradha Budhu, Ph.D., a staff scientist in the laboratory of Xin Wei Wang, Ph.D., head of the Liver Carcinogenesis Section of NCI's Center for Cancer Research (CCR). "Identifying new diagnostic and prognostic biomarkers for liver cancer is a first step in alleviating the dismal outcome of this disease."

MicroRNAs, or miRNAs, have been implicated in various aspects of human disease, including cancer. Their abundance in different tissues and cancer types indicate that miRNAs are functionally significant and have the potential to be used as cancer biomarkers. Since miRNAs can effectively regulate the activity of multiple cancer-related genes and pathways, they are prime candidates for coordinating the intricate events that lead to the spread of cancer, which is known as metastasis.

In this study, Budhu and her colleagues used miRNA microarray techniques, which allows researchers to examine the expression of thousands of genes simultaneously. They analyzed the miRNA expression profiles (shows the extent to which individual miRNAs are turned on or off) in cancerous and noncancerous liver samples from 131 patients with or without metastasis who underwent surgery at the Liver Cancer Institute and Zhongshan Hospital in Shanghai. The analysis revealed a set of 20 miRNAs with different patterns of expression in tumors with metastasis compared to tumors without metastasis. MiRNAs are capable of regulating the expression of one or more genes, including cancer-related genes, potentially affecting multiple cell functions that could lead to malignancy.

"This is an important and unique finding because it is the first study to show that miRNAs play a significant role in liver metastasis," explained Budhu. "In fact, miRNAs have not previously been related to cancer spread in any other organ."

Using the new gene expression profile, the researchers found that patients with the metastasis-miRNA profile had a two-fold higher risk of shorter survival compared to those without the profile. This latest finding in hepatocellular carcinoma, or HCC, in combination with earlier research by this team on early stage HCC and the tumor microenvironment, suggests a real potential for increasing the accuracy of liver cancer diagnosis and prognosis, as well as in monitoring recurrence.

"MiRNAs are also very stable molecules, which is an ideal property that could allow for more dependable measurements in clinical diagnostic or prognostic methods. Since miRNAs can affect multiple genes, including those related to cancer, they are also promising new targets for therapeutic approaches to liver cancer treatment," said Budhu.

HCC is the most common liver cancer diagnosed in adults and has a high prevalence in Asian and African populations. The rate of new HCC cases has been rising over the past 10 years in the United States and occurs twice as often in men as in women. HCC is a very aggressive disease; patients usually survive less than one year after diagnosis. In 2007, an estimated 19,160 Americans were newly diagnosed with liver cancer and an estimated 16,780 people died of the disease.

For more information about cancer, please visit the NCI website at http://www.cancer.gov, or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

For more information on Dr. Wang's research, go to http://ccr.cancer.gov/staff/staff.asp?profileid=5764.

For more information on Dr. Budhu's research, go to http://ccr.cancer.gov/staff/staff.asp?profileid=6709.

The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.


http://www.nih.gov/news/pr/jan2008/nci-07a.htm

References:

Budhu A, Jia H, Forgues M, Liu C, Goldstein D, Lam A, Zanetti KA, Ye Q, Qin L, Croce CM, Tang ZY, Wang, XW. Identification of Metastasis-related MicroRNAs in Hepatocellular Carcinoma HEP-07-1296. Hepatology. Online January 7, 2008. Vol. 47 No. 1.

Budhu A, Forgues M, Ye Q, Jia H, He P, Zanetti KA, Kammula US, Chen Y, Qin L, Tang Z, and Wang XW. Prediction of venous metastases, recurrence and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. August 2006, Vol. 10, Issue 2.